Ken Cacciatore
Stock Analyst at TD Cowen
(0.30)
# 4,217
Out of 4,918 analysts
13
Total ratings
27.27%
Success rate
-28.39%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $14.29 | +249.90% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $5.71 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $14.16 | +41.24% | 4 | May 16, 2023 | |
| SCPH scPharmaceuticals | Initiates: Outperform | $25 | $5.21 | +379.85% | 1 | Dec 1, 2022 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $13.50 | +159.26% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | $50 | $3.53 | +1,316.43% | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | $50 | $3.06 | +1,533.99% | 1 | Oct 19, 2020 | |
| BHVN Biohaven | Initiates: Outperform | $45 | $14.71 | +205.91% | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | $460 | $15.16 | +2,934.30% | 1 | Mar 2, 2020 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $14.29
Upside: +249.90%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $5.71
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $14.16
Upside: +41.24%
scPharmaceuticals
Dec 1, 2022
Initiates: Outperform
Price Target: $25
Current: $5.21
Upside: +379.85%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $13.50
Upside: +159.26%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $3.53
Upside: +1,316.43%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $3.06
Upside: +1,533.99%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $14.71
Upside: +205.91%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $15.16
Upside: +2,934.30%